Trials / Completed
CompletedNCT02053636
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Institut de Recherches Internationales Servier · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to evaluate the objective response rate (ORR) of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified with 11q amplification, or FGFR1-non amplified without 11q amplification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lucitanib |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2017-03-01
- Completion
- 2017-04-04
- First posted
- 2014-02-04
- Last updated
- 2024-07-25
Locations
29 sites across 9 countries: Australia, Belgium, Canada, France, Germany, Hungary, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02053636. Inclusion in this directory is not an endorsement.